JARDIAMET 5 mg / 850 mg empagliflozin/metformin hydrochloride 5mg/850mg film coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

jardiamet 5 mg / 850 mg empagliflozin/metformin hydrochloride 5mg/850mg film coated tablet blister pack

boehringer ingelheim pty ltd - empagliflozin, quantity: 5 mg; metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: maize starch; copovidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 400 - jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin is appropriate (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties - clinical trials).,empagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death (see section 5.1 pharmacodynamic properties - clinical trials).,to prevent cardiovascular deaths, empagliflozin should be used in conjunction with other measures to reduce cardiovascular risk in line with the current standard of care.

JARDIAMET 5 mg / 500 mg empagliflozin/metformin hydrochloride 5mg/500mg film coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

jardiamet 5 mg / 500 mg empagliflozin/metformin hydrochloride 5mg/500mg film coated tablet blister pack

boehringer ingelheim pty ltd - empagliflozin, quantity: 5 mg; metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: maize starch; copovidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 400 - jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin is appropriate (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties - clinical trials).,empagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death (see section 5.1 pharmacodynamic properties - clinical trials).,to prevent cardiovascular deaths, empagliflozin should be used in conjunction with other measures to reduce cardiovascular risk in line with the current standard of care.

Sitagliptin/Metformin Hydrochloride Pinewood 50 mg/1000 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

sitagliptin/metformin hydrochloride pinewood 50 mg/1000 mg film-coated tablets

pinewood laboratories ltd - sitagliptin hydrochloride; metformin hydrochloride - film-coated tablet - metformin and sitagliptin

Sitagliptin/Metformin Hydrochloride Pinewood 50 mg/850 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

sitagliptin/metformin hydrochloride pinewood 50 mg/850 mg film-coated tablets

pinewood laboratories ltd - sitagliptin hydrochloride; metformin hydrochloride - film-coated tablet - metformin and sitagliptin

TRAJENTAMET 2.5 mg/850 mg linagliptin 2.5 mg / metformin hydrochloride 850 mg film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

trajentamet 2.5 mg/850 mg linagliptin 2.5 mg / metformin hydrochloride 850 mg film-coated tablet bottle

boehringer ingelheim pty ltd - linagliptin, quantity: 2.5 mg; metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: hypromellose; purified talc; colloidal anhydrous silica; magnesium stearate; copovidone; propylene glycol; titanium dioxide; arginine; iron oxide yellow; maize starch; iron oxide red - trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate, in patients inadequately controlled on metformin alone, or those already being treated and well controlled with the free combination of linagliptin and metformin. trajentamet is indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea. trajentamet is indicated in combination with an sglt2 inhibitor (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an sglt2 inhibitor. trajentamet is indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.

TRAJENTAMET 2.5 mg/850 mg linagliptin 2.5 mg / metformin hydrochloride 850 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

trajentamet 2.5 mg/850 mg linagliptin 2.5 mg / metformin hydrochloride 850 mg film-coated tablet blister pack

boehringer ingelheim pty ltd - linagliptin, quantity: 2.5 mg; metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: arginine; magnesium stearate; purified talc; copovidone; maize starch; iron oxide yellow; titanium dioxide; colloidal anhydrous silica; hypromellose; propylene glycol; iron oxide red - trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate, in patients inadequately controlled on metformin alone, or those already being treated and well controlled with the free combination of linagliptin and metformin. trajentamet is indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea. trajentamet is indicated in combination with an sglt2 inhibitor (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an sglt2 inhibitor. trajentamet is indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.

TRAJENTAMET 2.5 mg/500 mg linagliptin 2.5 mg / metformin hydrochloride 500 mg film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

trajentamet 2.5 mg/500 mg linagliptin 2.5 mg / metformin hydrochloride 500 mg film-coated tablet bottle

boehringer ingelheim pty ltd - linagliptin, quantity: 2.5 mg; metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; iron oxide yellow; hypromellose; titanium dioxide; copovidone; arginine; maize starch; purified talc; magnesium stearate; propylene glycol - trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate, in patients inadequately controlled on metformin alone, or those already being treated and well controlled with the free combination of linagliptin and metformin. trajentamet is indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea. trajentamet is indicated in combination with an sglt2 inhibitor (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an sglt2 inhibitor. trajentamet is indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.

TRAJENTAMET 2.5 mg/500 mg linagliptin 2.5 mg / metformin hydrochloride 500 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

trajentamet 2.5 mg/500 mg linagliptin 2.5 mg / metformin hydrochloride 500 mg film-coated tablet blister pack

boehringer ingelheim pty ltd - linagliptin, quantity: 2.5 mg; metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: hypromellose; iron oxide yellow; propylene glycol; copovidone; colloidal anhydrous silica; arginine; maize starch; purified talc; magnesium stearate; titanium dioxide - trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate, in patients inadequately controlled on metformin alone, or those already being treated and well controlled with the free combination of linagliptin and metformin.,trajentamet is indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea.,trajentamet is indicated in combination with an sglt2 inhibitor (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an sglt2 inhibitor.,trajentamet is indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.

SITAGLIPTIN/METFORMIN DOC 50 mg/850 mg film-coated tablets Malta - English - Medicines Authority

sitagliptin/metformin doc 50 mg/850 mg film-coated tablets

doc generici srl via turati, 40-20121, milano, italy - sitagliptin, metformin hydrochloride - film-coated tablet - sitagliptin 50 mg metformin hydrochloride 850 mg - drugs used in diabetes

SITAGLIPTIN/METFORMIN DOC 50 mg/1000 mg film-coated tablets Malta - English - Medicines Authority

sitagliptin/metformin doc 50 mg/1000 mg film-coated tablets

doc generici srl via turati, 40-20121, milano, italy - sitagliptin, metformin hydrochloride - film-coated tablet - sitagliptin 50 mg metformin hydrochloride 1000 mg - drugs used in diabetes